Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 5, 1997, Pages 826-833

  Pimstone, Simon N ^a   Defesche, Joep C ^b   Clee, Susanne M ^a   Bakker, Henk D ^b   Hayden, Michael R ^a   Kastelein, John J P ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

children; familial defective apoB 100; familial hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0030948955     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.5.826     Document Type: Article

References (31)

1. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 7th edition. Toronto, Ontario, Canada: McGraw-Hill Publishing Co; 1995:1981-2030.
2. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A. 1987;84:6919-6923.
3. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apoB-100. Proc Natl Acad Sci U S A. 1989;86:587-591.
4. Pullinger CR, Hennessy LK, Chatterton JE, Lui W, Love JA, Mendel CM, Frost PH, Malloy MJ, Schumaker VN, Kane JP. Familial ligand defective apolipoprotein B: identification of a new mutation that decreases LDL-receptor binding affinity. Circulation. 1993;88:322. Abstract.
5. Nissen H, Hansen PS, Faergeman OS, Hørder M. Mutation screening of codon 3500 region of the apolipoprotein B gene by denaturing gradient-gel electrophoresis. Clin Chem. 1995;41:419-423.
6. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res. 1990;31:1337-1350.
7. Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, Seed M, Hamsten A, Humphries SE, Myant NB. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia and clinical characteristics of ten cases. Atherosclerosis. 1990;80:235-242.
8. Miserez AR, Keller U. Differences in phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:1719-1729.
9. Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest. 1986;86:1410-1414.
10. März W, Baumstark MW, Scharnagl H, Ruzicka V, Buxbaum S, Herwig J, Pohl T, Russ A, Schaaf L, Berg A, Böhles H-J, Usadel KH, Groß W. Accumulation of "small dense" low density lipoprotein (LDL) in a homozygous patient with familial defective apolipoprotein B-100 results from heterogeneous interaction of LDL subfractions with the LDL receptor. J Clin Invest. 1993;92:2922-2933.
11. Raugh G, Keller C, Korman B, Spengel H, Schuster H, Wolfram G, Zöllner N. Familial defective apolipoprotein B-100: clinical characteristics of 54 cases. Atherosclerosis. 1992;92:233-241.
12. Tybjaerg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis. 1992;96:91-107.
13. Defesche JC, Pricker KL, Hayden MR, Van der Ende B, Kastelein JJP. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Intern Med. 1993;153:2349-2356.
14. Rochlau P, Bernt E, Gruber W. Enzymatische Bestimming der Gesammtcholesterins in serum. J Clin Biochem. 1974;12:403-407.
15. Demacker PNM, Van Oppenraay JBHA, Baadenhuijsen H, Jansen AP. An improved semi-automated method for the colorimetric determination of triglycerides in serum. Clin Chim Acta. 1975;64:45-50.
16. Lopes-Virella MF, Stone J, Ellis S, Goldwell JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem. 1975;23:882-884.
17. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Marcovina S, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International federation of clinical chemistry standardization project for measurement of apolipoproteins A-1 and B. Clin Chem. 1991;37:1676-1682.
19. Defesche JC, Hoogendijk JE, de Visser M, de Visser O, Bolhuis PA. Genetic linkage of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease) to markers of chromosomes 1 and 17. Neurology. 1990;40:1450-1453.
20. Reymer PWA, Groenemeyer BE, Van der Burg R, Kastelein JJP. Apolipoprotein E genotyping on agarose gels. Clin Chem. 1995;41:1046-1047.
21. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1:445-446.
22. Defeshe JC, Lansberg PJ. The Molecular Basis and Treatment of Familial Hypercholesterolemia. Amsterdam, The Netherlands: University of Amsterdam; 1993. Thesis.
23. Lombardi P, Sijbrands E, Van de Giessen K, Smelt A, Kastelein JJP. Identification of mutations in the LDL-receptor by denaturing gradient gel electrophoresis. J Lipid Res. 1995;36:860-867.
24. Funke H, Rust S, Seedorf U, Brennhausen B, Chirazi A, Motti C, Assmann G. Homozygosity for familial defective apolipoprotein B-100 (FDB) is associated with lower plasma cholesterol concentrations than homozygosity for familial hypercholesterolemia (FH). Circulation. 1992;86(suppl I):I-691. Abstract.
25. Stampfer MJ, Sacks FM, Salvini S, Willet WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
26. Assouline L, Levy E, Feoli-Fonseca JC, Godbout C, Lambert M. Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population. Pediatrics. 1995;96:239-246.
27. Hansen PS, Meinertz H, Jensen HK, Fruergaard P, Launbjerg J, Klausen IC, Lemming L, Gerdes U, Gregerson N, Faergeman O. Characteristics of 46 heterozygous carriers and 57 unaffected relatives in five Danish families with familial defective apolipoprotein B-100. Arterioscler Thromb. 1994;14:207-213.
28. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb. 1991;11:290-297.
29. Tonstad S, Leren TP, Siverton M, Ose L. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vasc Biol. 1995;15:1009-1014.
30. Tell GS, Mittelmark MB, Vellar OD. Cholesterol, high density lipoprotein cholesterol and triglycerides during puberty: the Oslo Youth Study. Am J Epidemiol. 1985;122:750-761.
31. Rubinsztein DC, Raal FJ, Seftel HC, Pilcher G, Coetzee GA, van der Westhuyzen DR. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apoB-100. Arterioscler Thromb. 1993;13:1076-1081.